ArticleBMC pulmonary medicine2023
Clinical impacts of sarcopenic obesity on chronic obstructive pulmonary disease: a cross-sectional study.
Article in BMC pulmonary medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Prevalence of sarcopenia in COPD patients using AWGS criteria among Asian populations: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Risk Factors of Sarcopenia in COPD Patients: A Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2024Pooled it
- Assessing Lifestyle Goal Setting in Patients with COPD.International journal of chronic obstructive pulmonary disease · 2026Trial
- Type 1 Diabetes Mellitus as a Model of Body Composition Transformation: Pathogenetic Unity of Combined Phenotypes.International journal of molecular sciences · 2026Review
- The Emerging Utility of Bioimpedance in Patients with Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2026Article
- Cardiometabolic Comorbidities in COPD: Focus on Diabetes, GLP-1 Receptor Agonists, SGLT-2 Inhibitors and Antidiabetic Drugs.Journal of clinical medicine · 2026Review
- Calprotectin Is a Circulating Biomarker and Potential Therapeutic Target for Sarcopenia in Chronic Obstructive Pulmonary Disease.Journal of cachexia, sarcopenia and muscle · 2026Article
- Loss of muscle and bone mass with increased adiposity and fractures in patients with chronic obstructive pulmonary disease: A 5-year follow-up cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Observational
- High BMI and COPD Outcomes in Alpha-1 Antitrypsin Deficiency.CHEST pulmonary · 2025Article
- The relationship between sarcopenic obesity and cognitive functionality among inpatients with stable schizophrenia.PloS one · 2025Article
- Association of weight-adjusted waist index with preserved ratio impaired spirometry and all-cause mortality.Frontiers in nutrition · 2025Article
- Association Between Weight-Adjusted Waist Index and Emphysema in Adults in the United States: A Cross-Sectional Study Involving 44,949 Participants.Advances in respiratory medicine · 2024Article
- Malnutrition and Obesity in Patients with COPD Exacerbation, Insights from the National Inpatient Sample.The open respiratory medicine journal · 2024Article
- Association between lipid accumulation product and chronic obstructive pulmonary disease: a cross-sectional study based on U.S. adults.Frontiers in nutrition · 2024Article
- Associations of sarcopenic obesity with chronic lung disease and peak expiratory flow in middle-aged and older adults: A cohort study based on CHARLS and ELSA.Chronic respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 3 countries.
Funding
Abstract
backgroundSarcopenia and obesity are two abnormal body composition phenotypes, and sarcopenic obesity (SO) is characterized by both low skeletal muscle mass (sarcopenia) and high adiposity (obesity). SO negatively influences the clinical status of patients with chronic obstructive pulmonary disease (COPD). However, the studies exploring the prevalence and clinical effects of SO in COPD patients are limited. Our study aimed to elucidate the prevalence and impact of SO on COPD patients.
methodsIn this cross-sectional study, the pulmonary function, St. George's Respiratory Questionnaire, exercise tolerance, body composition, and serum levels of resistin and TNF-α were assessed in 198 COPD patients. The clinical value of serum resistin and TNF-α for predicting SO in patients with COPD was evaluated.
resultsIn the 198 patients with COPD, the prevalence rates of sarcopenia, obesity, and SO in COPD patients were 27.27%, 29.8%, and 9.6%, respectively. Patients with SO experienced more severe symptoms of dyspnea and worse health related quality of life. The expression of resistin increased in patients with SO compared to other patients. The AUC value of serum resistin level for predicting SO was 0.870 (95% CI: 0.799-0.940). BMI (OR: 1.474, 95% CI: 1.124-1.934) and resistin (OR: 1.001, 95% CI: 1.000-1.002) levels were independent risk factors of SO in patients with COPD in Multivariate analysis.
conclusionThe prevalence rates of SO in COPD patients was 9.6%. COPD accompanied by SO is significantly associated with worse pulmonary function and poor physical performance. Serum resistin may be a potential adjunct for predicting SO in COPD patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.